Study #2012-0358
A Phase I Trial of WP1066
MD Anderson Study Status
Enrolling
Treatment Agent
STAT3 Inhibitor WP1066
Description
This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting worse. STAT3 inhibitor WP1066 may stop the growth of tumor cells and modulate the immune system.
信息和下一步
Disease:
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma, Recurrent Malignant Glioma
研究阶段：
I
医师名称：
Amy Heimberger
部：
神经外科
有关临床试验的一般问题：
1-877-632-6789
Help #EndCancer
现在给予
您的礼物将有助于提出巨大的差异。
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson Blood Donor Center locations are being held by appointment only.